NEW YORK (GenomeWeb) – Rosetta Genomics today announced that it has completed its previously announced acquisition of CynoGen, a molecular diagnostics firm doing business as PersonalizeDx.

Rosetta bought the firm from Prelude Corp., which recently acquired CynoGen from Abbott, in exchange for $2 million, 500,000 of Rosetta's ordinary shares, and certain undisclosed assets and services.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.